Direct emissions
142,884
tCO2e
C
Centrient Pharmaceuticals
Explore carbon emissions data for Centrient Pharmaceuticals. Mycelium helps you review reported emissions, disclosure status, Scope 1, Scope 2 and Scope 3 data, climate targets and sustainability information in one company profile.
This profile brings together available carbon emissions data for Centrient Pharmaceuticals, including reported figures, modelled estimates, disclosure documents and sustainability indicators, so you can review its emissions and compare its performance against similar companies. Read how we source and check this data.
Emissions
Carbon emissions
Total yearly emissions across all scopes
747,119 tCO2e (Market Based)
Scope 1
tCO2e
142,884
Scope 2 (Market Based)
tCO2e
118,053
Scope 3 total
tCO2e
486,182
Scope 3 reported
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
Provenance
Emissions
Factors
1,441,174
kgCO2e / £M
Supplier specific emission factors (kgCO2e / £M)
Modelled
Reported
Scope 1 + 2
Direct + purchased energy
503,341
503,341
Upstream
+ upstream Scope 3
1,289,779
1,288,269
Total
+ all Scope 3
1,441,174
1,344,534
Which figure should I use?
Use Modelled. It is the most complete view: any categories the company hasn't disclosed are filled with industry-typical estimates, so a transparent company isn't unfairly penalised against one that simply hasn't reported.
Reported counts only emissions the company has filed itself. A blank or low Reported cell doesn't mean those emissions don't exist, just that the company hasn't disclosed them.
When Reported sits close to Modelled, that is a positive signal. The company has disclosed most of its salient emissions and there's little gap for the model to fill. Even then, Modelled is the right figure to use for a like-for-like comparison across companies.
Sustainability
Snapshot
Based on reported data, retrieved with AI
- Centrient Pharmaceuticals reported 747,119 tCO₂e in 2024.
- Scope 3 accounted for 65% of emissions.
- Reported across 10 of 15 GHG Protocol Scope 3 categories.
- Scope 2 reported under the market based methodology.
According to available emissions disclosures, Centrient Pharmaceuticals reported total yearly emissions of 747,119 tCO₂e in 2024. Scope 3 emissions accounted for 65% of reported output, indicating supply chain activity, purchased goods and services, business travel, and wider operational dependencies were the most significant contributors to the company's carbon footprint.
The company achieved a Mycelium Score of 1.0, placing it well below average for its sector for sustainability performance, and received a transparency score of 36.0, pointing to very little public detail on their key emissions.
Total Emissions across all scopes
747,119 tCO2e (Market Based)
Scope 1 emissions
Direct emissions from sources the company owns or controls, such as fuel use, facilities and vehicles.
Scope 2 emissions
Indirect emissions from purchased energy, including electricity, heating and cooling.
Location based
193,783
tCO2eMarket based
118,053
tCO2eScope 3 emissions
Wider value chain emissions across the 15 GHG Protocol categories, from purchased goods and business travel to investments, where reported.
Cat 1
Purchased goods & services
289,710
tCO2eCat 2
Capital goods
5,769
tCO2eCat 3
Fuel & energy related activities
81,897
tCO2eCat 4
Upstream transportation & distribution
21,190
tCO2eCat 5
Waste generated in operations
5,402
tCO2eCat 6
Business travel
1,522
tCO2eCat 7
Employee commuting
1,425
tCO2eCat 8
Upstream leased assets
783
tCO2eCat 9
Downstream transportation & distribution
1,804
tCO2eCat 10
Processing of sold products
26,554
tCO2eCat 11
Use of sold products
46,968
tCO2eCat 12
End-of-life treatment of sold products
809
tCO2eCat 13
Downstream leased assets
783
tCO2eCat 14
Franchises
783
tCO2eCat 15
Investments
783
tCO2e5 values were derived via Mycelium's normalisation process rather than reported by the company. Cells marked “–” were not disclosed.
Contact Info
Browse carbon emissions data by industry
Jump straight into the sectors users explore most, or view all industries.
How scoring works
How the Mycelium Score is calculated
The Mycelium Score is out of 10. Up to 6.5 points reflect carbon intensity vs sector peers (emissions normalised against revenue). The remaining 3.5 reflect data quality: third-party verified, profile claimed by the company, and full disclosure across all reporting categories.
A higher score means lower carbon intensity than sector peers, backed by data that's third-party verified, claimed by the company, and fully disclosed. Centrient Pharmaceuticals's score sits at the top of this page and in the score panel.
How the Transparency Score is calculated
The Transparency Score measures how much of a company's key emissions data is publicly disclosed, graded from A (very high) down to F (very low). Crucially, it weights each gap by how material that bucket is for the company's industry, so an undisclosed category where the bulk of emissions sit hurts far more than a minor one.
For Centrient Pharmaceuticals, the single biggest gap is Use of sold products (Scope 3 Category 11). Mycelium estimates it accounts for around 6% of the company's total footprint, typically the largest source of emissions for a Health Care company, yet it hasn't been disclosed. Leaving a bucket this large unreported is what's holding the transparency score down.
In total, roughly 6% of Centrient Pharmaceuticals's estimated emissions sit in categories it hasn't reported. Disclosing these would be the fastest way to raise the transparency score.
Read the full scoring methodology
Our white paper covers exactly how the Mycelium Score and Transparency Score are calculated, including the normalisation process and what earns a 10/10.
Download the white paper (PDF)
Centrient Pharmaceuticals carbon emissions FAQs
What are Centrient Pharmaceuticals's carbon emissions?
In its 2024 reporting year, Centrient Pharmaceuticals disclosed total emissions of 747,119 tCO2e across all scopes. Scope 3 accounted for the largest share, around 65% of the total.
Does Centrient Pharmaceuticals report Scope 1, Scope 2 and Scope 3 emissions?
For 2024, Centrient Pharmaceuticals's available disclosure covers Scope 1 (142,884 tCO2e), Scope 2 (118,053 tCO2e), Scope 3 across 10 of the 15 GHG Protocol categories. Figures not reported by the company are shown as modelled estimates and labelled as such.
How transparent is Centrient Pharmaceuticals's emissions reporting?
Centrient Pharmaceuticals has a Mycelium transparency score of 36 out of 100. The score weights each emissions category by how material it is for the company's industry, so it reflects whether the disclosures that matter most have been made.
Is Centrient Pharmaceuticals sustainable?
Mycelium measures sustainability through carbon emissions data rather than giving a yes or no verdict. Centrient Pharmaceuticals has a Mycelium Score of 1 out of 10, which reflects its emissions intensity against sector peers together with how transparent and well-verified its reporting is. The emissions figures, disclosure documents and climate targets on this page give the fuller picture.
Is Centrient Pharmaceuticals environmentally friendly?
Carbon emissions are one measurable part of environmental impact, and the part Mycelium tracks. Centrient Pharmaceuticals disclosed 747,119 tCO2e for 2024, and its Mycelium Score of 1 out of 10 shows how that performance compares with similar companies in its sector.
Learn more about our methodology and where this data comes from.
